1. Home
  2. RVPH vs SCWO Comparison

RVPH vs SCWO Comparison

Compare RVPH & SCWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • SCWO
  • Stock Information
  • Founded
  • RVPH 2006
  • SCWO 2021
  • Country
  • RVPH United States
  • SCWO United States
  • Employees
  • RVPH N/A
  • SCWO N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • SCWO Environmental Services
  • Sector
  • RVPH Health Care
  • SCWO Utilities
  • Exchange
  • RVPH Nasdaq
  • SCWO Nasdaq
  • Market Cap
  • RVPH 32.8M
  • SCWO 56.4M
  • IPO Year
  • RVPH N/A
  • SCWO N/A
  • Fundamental
  • Price
  • RVPH $0.40
  • SCWO $0.19
  • Analyst Decision
  • RVPH Strong Buy
  • SCWO
  • Analyst Count
  • RVPH 5
  • SCWO 0
  • Target Price
  • RVPH $9.00
  • SCWO N/A
  • AVG Volume (30 Days)
  • RVPH 3.4M
  • SCWO 1.4M
  • Earning Date
  • RVPH 08-13-2025
  • SCWO 08-13-2025
  • Dividend Yield
  • RVPH N/A
  • SCWO N/A
  • EPS Growth
  • RVPH N/A
  • SCWO N/A
  • EPS
  • RVPH N/A
  • SCWO N/A
  • Revenue
  • RVPH N/A
  • SCWO $673,267.00
  • Revenue This Year
  • RVPH N/A
  • SCWO $5,945.19
  • Revenue Next Year
  • RVPH N/A
  • SCWO $106.82
  • P/E Ratio
  • RVPH N/A
  • SCWO N/A
  • Revenue Growth
  • RVPH N/A
  • SCWO 161.19
  • 52 Week Low
  • RVPH $0.30
  • SCWO $0.16
  • 52 Week High
  • RVPH $4.28
  • SCWO $1.99
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 33.44
  • SCWO 34.92
  • Support Level
  • RVPH $0.35
  • SCWO $0.16
  • Resistance Level
  • RVPH $0.83
  • SCWO $0.44
  • Average True Range (ATR)
  • RVPH 0.06
  • SCWO 0.05
  • MACD
  • RVPH -0.01
  • SCWO -0.02
  • Stochastic Oscillator
  • RVPH 17.36
  • SCWO 15.11

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

About SCWO 374Water Inc.

374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.

Share on Social Networks: